BRISBANE, AustraliaProgen Industries is conducting a phase I trial
combining its cancer drug PI-88 with docetaxel (Taxotere) in patients with
advanced malignancies. The trial is taking place at the University of Colorado
Cancer Center, Denver, with Scott Holden, MD, as principal investigator, Progen
said in a news release.
PI-88 is a semisynthetic sulfated oligosaccharide that has several modes of
action. In animal models it has been shown to prevent angiogenesis by
inhibiting fibroblast growth factor, and to block metastasis by inhibiting the
enzyme heparinase, which allows cancer cells to escape blood vessels. It also
stimulates sustained release of TFPI (tissue factor pathway inhibitor), a
natural inhibitor of angiogenesis, from cells lining the blood vessel wall.